Pain scale

Pelvic Rehabilitation Medicine is Now In-Network with Blue Cross Blue Shield

Retrieved on: 
Monday, November 14, 2022
PALM, BCBS, Pain, Pain scale, Infertility, MD, Woman, Blue Cross Blue Shield Association, PRM, Entrepreneurship, Man, Inflammation, Medicine, Industry, Endometriosis, Insurance, Patient, Pelvic pain, CEO, Chief medical informatics officer, Diagnosis, Birth control

WEST PALM BEACH, Fla., Nov. 14, 2022 /PRNewswire/ -- Pelvic Rehabilitation Medicine (PRM), the premier physician practice focused on treating persistent pelvic pain through outpatient settings across the country, is proud to announce that it is now in-network with Blue Cross Blue Shield (BCBS) in Florida, Texas, Illinois, Michigan, and Georgia. As the first integrative pelvic pain solution to be available in-network, PRM is thrilled to significantly expand access to care for men and women suffering from chronic pelvic pain – a health crisis that affects 15% of women and 10% of men. 

Key Points: 
  • WEST PALM BEACH, Fla., Nov. 14, 2022 /PRNewswire/ -- Pelvic Rehabilitation Medicine (PRM), the premier physician practice focused on treating persistent pelvic painthrough outpatient settings across the country, is proud to announce that it is now in-network with Blue Cross Blue Shield (BCBS) in Florida, Texas, Illinois, Michigan, and Georgia.
  • Therefore, increasing access to diagnosis and treatment is at the core of our mission," shared Dr. Allyson Shrikhande, Co-Founder and Chief Medical Officer, Pelvic Rehabilitation Medicine.
  • "In the past, pelvic pain issues haven't typically been covered by insurance, and those inflicted were left to suffer in silence."
  • Pelvic Rehabilitation Medicine (PRM) is a premier, multi-disciplinary physician practice focused on treating persistent pelvic pain related symptoms and conditions for women and men through outpatient settings across the country.

Scientists Identify Hidden Factor That Help Pain after Fibromyalgia

Retrieved on: 
Monday, November 14, 2022
Tao, Gait, Postural orthostatic tachycardia syndrome, Awareness, Pain scale, Association, Grammatical mood, Academy of Family Physicians of India, NP-hardness, Parkinson's disease, Massage, Literature review, Fatigue, Report, Pinealectomy, Spondylosis, Prostate cancer, Neck pain, Pectus carinatum, Metastasis, Posture, Electromyography, Patient, Quality of life, Low back pain, Signs and symptoms, Back pain, Hidden, Multimedia, Dizziness, Diagnosis, Domestic violence, Breast cancer, Sleep, Knee pain, Deformity, Rehabilitation, NEW, Foramen magnum, ECP, American Journal, Thought, Headache, Bell's palsy, Schwannoma, Pharmaceutical industry, Medical device, Poultry, Birth control, Healthcare, Online shopping, Medicine, Fibromyalgia

NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Scientists have identified treating cervical spondylosis helps patients with fibromyalgia stand up and live again.

Key Points: 
  • NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Scientists have identified treating cervical spondylosis helps patients with fibromyalgia stand up and live again.
  • A woman presented with a chronic headache, severe neck pain, shoulder pain, and back pain lasting for 2 years after experiencing domestic violence.
  • The widespread pain in fibromyalgia can lead to confused thinking and a lack of awareness of cervical spondylosis.
  • According to the researchers, this suggests chiropractic treatment blocked noxious inputs coming from pain sources, corrected pain thresholds, and lowered excitability, thereby eradicating fibromyalgia symptoms.

EQS-News: The NIH Has Given BioRestorative Therapies A Stamp Of Approval

Retrieved on: 
Friday, November 11, 2022
Transfer, Federal, Qualcomm, QCOM, Lijun International Pharmaceutical (Holding) Co. Ltd., Innovation, Small Business Innovation Research, Biomedical engineering, Food, STTR, Diabetes, Advertising, Food and Drug Administration, Research, Adipose tissue, Department, NIH, Small Business Administration, Obesity, Biomedicine, Stem cell, SBIR, NASDAQ, Solution, National Institute, Company, PEG, B cell, Pain scale, Pain, Patient, Small business, National Institutes of Health, Washington University in St. Louis, Map, FDA, Pharmaceutical industry, Bank

BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.

Key Points: 
  • BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.
  • This fascinating opportunity presents a study that is highly suggestive of the potential outcomes for which they are currently processing.
  • BioRestorative Therapies Has Joined The Leagues Of 23andMe, Qualcomm and Naviscan
    In September 2021, BioRestorative was awarded a Small Business Technology Transfer (STTR) phase I grant for $256,000.
  • With the recent grants BioRestorative Therapies has received, the NIH has given the company a stamp of approval.

Applied Molecular Transport Announces FDA Orphan Drug Designation Granted to AMT-101 for Treatment of Pouchitis

Retrieved on: 
Thursday, November 10, 2022
Quality of life, AMTI, SAN, GLOBE, Rheumatoid arthritis, Ulcerative colitis, Marketing, U.S. Securities and Exchange Commission, Pouchitis, Pain scale, Abdominal pain, FDA, Food, Nasdaq, IE, Orphan, UC, Technology, Population, CMV, Incontinence, Magazine, Securities Act of 1933, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fecal incontinence, IBD, SEC, Chronic pain, Safety, Ulcer, Securities Exchange Act of 1934, Patient, CA, Kelly Gebo, IPAA, Inflammation, Autoimmunity, Disease, Program, AMT, Terminology, Colectomy, OR, GMP, Growth, Security (finance), Drug Quality and Security Act, Cytomegalovirus, RA, SAE, Pharmaceutical industry, Vaccine

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for AMT-101 in patients with pouchitis, an indication with significant unmet medical need and no current FDA-approved products.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for AMT-101 in patients with pouchitis, an indication with significant unmet medical need and no current FDA-approved products.
  • Rapid onset of stool frequency response was demonstrated as early as week 2 in both dosage groups and was maintained through the duration of treatment.
  • Acute pouchitis often responds to antibiotic treatment but up to 50% of pouchitis patients develop chronic pouchitis where patients often relapse on or do not respond to antibiotic therapy.
  • Active transport is an efficient mechanism that uses the cells own machinery to transport materials across the IE barrier.

ROME Therapeutics Demonstrates Efficacy of its Novel LINE-1 Reverse Transcriptase Inhibitor in Translational Models of Autoimmune Disease

Retrieved on: 
Thursday, November 10, 2022
Biotechnology, Health, Oncology, Health, Genome, Pain scale, American College of Rheumatology, Cytosol, Therapy, DNA, RNA, Degenerative disease, ERT, Machine learning, Cancer, Disease, Program, Virology, Biotechnology, ACR, Autoimmune disease, American College, Pharmaceutical industry, Vaccine

LINE-1 reverse transcriptase is an endogenous reverse transcriptase (eRT) encoded by repetitive sequences in the human genome.

Key Points: 
  • LINE-1 reverse transcriptase is an endogenous reverse transcriptase (eRT) encoded by repetitive sequences in the human genome.
  • Since excess activation of these pathways can lead to autoimmune disease, eRT inhibitors have great potential to improve pathological outcomes.
  • Through rational structure-based drug design, ROME identified novel, selective and potent inhibitors of LINE-1 reverse transcriptase.
  • Endogenous reverse transcriptases encoded by repetitive sequences in the human genome are increasingly implicated in many difficult-to-treat diseases, including autoimmune disease.

Insights on the Cardiac Rehabilitation Global Market to 2028 - Featuring Technogym, Omron, Baxter International and Halma Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 10, 2022
Health, Cardiology, Quality of life, Hospital, Cardiac rehabilitation, Pain scale, Statistics, Baxter International, Prevalence, Cardiology, Center, Risk, Diabetes, Smoking, Incidence, Population, Degenerative disease, Korea Disease Control and Prevention Agency, Government, Fatality, Patient, Growth, Infarction, Cardiovascular disease, Industry, Life Fitness, SGB-SMIT Group, CAGR, Medical device, Health insurance

The Global Cardiac Rehabilitation Market size is expected to reach $2.4 billion by 2028, rising at a market growth of 5.3% CAGR during the forecast period.

Key Points: 
  • The Global Cardiac Rehabilitation Market size is expected to reach $2.4 billion by 2028, rising at a market growth of 5.3% CAGR during the forecast period.
  • The best aspect of recovery after a heart attack or other heart condition is cardiac rehabilitation.
  • One of the key elements driving the growth of the cardiac rehabilitation market is the rise in popularity of e-cardiology and e-health.
  • The development of the cardiac rehabilitation market is further fueled by the infrastructural improvements done in numerous healthcare sectors across different nations.

Global Nephroblastoma Treatment Market Report 2022: Increasing R&D Activities Driving Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 8, 2022
Health, Pharmaceutical, Organization, Wilms' tumor, Oncology, Sun Pharma, Pediatrics, Nausea, Industry, Dactinomycin, American Journal of Clinical Oncology, Swelling, Patient, MD, Department, CAGR, Benign tumor, Merck & Co., Kidney, City, Etoposide, Vincristine, Nephrectomy, Cyclophosphamide, Fever, Journal, Alvogen, US, Histology, Region, Carboplatin, Pfizer, Stomach, Merck, Pain scale, Market share, RCC, Neoplasm, Marketing, Research, Constipation, Medical imaging, Pharmaceutical industry

The "Nephroblastoma Treatment Market, by Type, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nephroblastoma Treatment Market, by Type, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Nephroblastoma, also known as Wilms tumor, is the most prevalent kind of renal cancer among pediatrics.
  • The most typical childhood abdominal cancer, wilms tumor, often manifests between the ages of 3 and 5.
  • Increasing research and development activities by various organizations and researchers to develop treatment options for nephroblastoma are expected to drive the market growth over the forecast period.

Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLD

Retrieved on: 
Monday, November 7, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Food, Breakthrough therapy, Pregnancy, Safety, Symptoms of COVID-19, Skin, Cholestasis, Stomach, FSV, European Directive on Traditional Herbal Medicinal Products, Webcast, Liver, Nausea, FDA, Patient, SEC, Form, Company, Primary biliary cholangitis, Professor, Cholestatic pruritus, Royal commission, Vitamin, Event, CHMP, Diarrhea, Publication, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, VISTAS, Pain, Bone, Biliary atresia, Vomiting, IBAT, Institute of Liver and Biliary Sciences, Alagille syndrome, Primary sclerosing cholangitis, PFIC, Pain scale, Vitamin A, Form 10-Q, Form 10-K, Abdomen, Infant, Gastrointestinal bleeding, Research, European Committee on Antimicrobial Susceptibility Testing, Spiroplasma mirum, European Commission, Poster, Liver injury, Pharmaceutical industry, RISE

The youngest ALGS patient in the study was two months of age, with an average age of seven months.

Key Points: 
  • The youngest ALGS patient in the study was two months of age, with an average age of seven months.
  • Based on the safety and tolerability data observed in RISE, LIVMARLI may be an effective treatment option for ALGS patients as young as two months of age.
  • The objective of the study was to report real-world safety observations for patients enrolled in the LIVMARLI global expanded access program.
  • LIVMARLI has received Breakthrough Therapy designation for ALGS and PFIC type 2 and orphan designation for ALGS, PFIC and biliary atresia.

Gelesis to Report Third Quarter 2022 Financial Results on November 14, 2022

Retrieved on: 
Monday, November 7, 2022
General Health, Fitness & Nutrition, Health, Other Health, Patient, Gel, Company, Exercise, Diet, Multimedia, Obesity, Cellulose, FDA, Functional constipation, NASH, Type 2 diabetes, NYSE, Webcast, Incidence, Abdomen, Gelesis, Allergy, GLS, Pain scale, Nature, Flatulence, BMI, Food, Use, Non-alcoholic fatty liver disease, Citric acid, Body mass index, Diarrhea, NAFLD, Absorption, Defecation, Gelatin, Human, Dietary supplement, Hydrogel

Gelesis Holdings, Inc. (NYSE:GLS) (Gelesis or the Company), the maker of Plenity for weight management, today announced that the Company will report financial results for the third quarter ended September 30, 2022, on November 14, 2022 prior to the market open.

Key Points: 
  • Gelesis Holdings, Inc. (NYSE:GLS) (Gelesis or the Company), the maker of Plenity for weight management, today announced that the Company will report financial results for the third quarter ended September 30, 2022, on November 14, 2022 prior to the market open.
  • Gelesis management will host a live conference call and webcast at 8:30 a.m.
  • View the full release here: https://www.businesswire.com/news/home/20221107005166/en/
    Gelesis is a consumer-centered biotherapeutics company and the maker of Plenity for weight management.
  • (Photo: Business Wire)
    The live call can be accessed via webcast on the Events & Presentations section of the Gelesis Investor Relations website at https://ir.gelesis.com/ .

American Shared Hospital Services Announces Third Quarter 2022 Earnings Conference Call

Retrieved on: 
Thursday, November 3, 2022
Proton therapy, Company, CA, Pectus carinatum, Call, GLOBE, Trigeminal neuralgia, NYSE, IGRT, Pain scale, IMRT, AMS, Radiosurgery, Malignancy, Medical imaging, Conference

SAN FRANCISCO, CA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its third quarter 2022 financial results on Thursday November 10th, 2022 at 3:00 pm ET / 12:00 pm PT. The third quarter 2022 financial results press release will be issued before the market open on Thursday, November 10, 2022.

Key Points: 
  • Conference Call on Thursday November 10th, 2022 at 3:00 pm ET / 12:00 pm PT
    SAN FRANCISCO, CA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its third quarter 2022 financial results on Thursday November 10th, 2022 at 3:00 pm ET / 12:00 pm PT.
  • The third quarter 2022 financial results press release will be issued before the market open on Thursday, November 10, 2022.
  • To participate, please call 1 (844) 413-3972 at least 10 minutes prior to the start of the call and ask to join the American Shared Hospital Services call.
  • About American Shared Hospital Services (NYSE American: AMS)
    American Shared Hospital Services is a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services.